F. Hoffmann-La Roche Ltd: Roche presents new data demonstrating the potential benefit of glofitamab and Lunsumio as fixed-duration, off-the-shelf treatment options for lymphoma

Data showcase the potential of glofitamab and Lunsumio to address diverse patient needsData presented at ASH 2022 and simultaneously published in the New England Journal of Medicine showed that glofitamab

Related Keywords

Japan ,United States ,Switzerland ,America ,American ,Levi Garraway ,Mabthera Rituxan ,Gazyva Gazyvaro ,Sabine Borngr ,Gerard Tobin ,Bruno Eschli ,Venclexta Venclyxto ,Birgit Masjost ,Loren Kalm ,Nathalie Altermatt ,Genentech ,European Commission ,Drug Administration ,Head Of Global Product Development ,American Society Of Hematology ,Roche Group ,European Medicines Agency ,New England Journal ,American Society ,Annual Meeting ,Chief Medical Officer ,Global Product ,Priority Review ,Dow Jones Sustainability Indices ,Chugai Pharmaceutical ,Largeb Cell Lymphoma Who Are ,Complete Remission ,Fixed Course Glofitamab ,Refractory Diffuse Largeb Cell ,Manageable Safety Profile ,Refractory Follicular Lymphoma Who Received ,Updated Results ,Pivotal Phase ,Mosunetuzumab Is Active ,B Cell Non Hodgkin Lymphomas ,Demonstrate Promising Efficacy ,Durable Complete Responses ,Unfit Patients ,Previously Untreated Diffuse Largeb Cell ,Polatuzumab Vedotin Is Effective ,Patients Aged Roche Group Media ,Hoffmann ,Oche ,Presents ,Data ,Emonstrating ,Potential ,Benefit ,Glofitamab ,Lunsumio ,Ixed ,Uration ,Shelf ,Treatment ,Options ,Lymphoma ,